NuCana BioMed Limited: NuCana's Acelarin achieves high clinical activity and durable disease control in patients with recurrent ovarian cancer
June 06, 2016 14:17 ET | NuCana BioMed Limited
CHICAGO, June 6, 2016 (GLOBE NEWSWIRE) -- NuCana today presented positive interim results of a Phase Ib clinical study of Acelarin® (NUC-1031) in combination with carboplatin in patients with...